argenx (NASDAQ:ARGX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of argenx (NASDAQ:ARGX) in a research note released on Wednesday, Benzinga reports. The firm currently has a $451.00 price objective on the stock.

A number of other analysts have also commented on the company. Raymond James lowered their price objective on argenx from $580.00 to $520.00 and set a strong-buy rating for the company in a research report on Thursday, December 21st. Citigroup dropped their price target on shares of argenx from $610.00 to $591.00 and set a buy rating for the company in a research note on Wednesday, November 29th. Stifel Nicolaus raised their price objective on shares of argenx from $557.00 to $560.00 and gave the company a buy rating in a research note on Monday, December 18th. Wells Fargo & Company lifted their target price on shares of argenx from $472.00 to $478.00 and gave the stock an overweight rating in a report on Tuesday, February 20th. Finally, Wolfe Research assumed coverage on argenx in a research note on Thursday, February 15th. They issued a peer perform rating on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $530.74.

argenx Trading Up 0.3 %

Shares of NASDAQ ARGX opened at $398.59 on Wednesday. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The company has a 50-day moving average of $387.39 and a two-hundred day moving average of $435.23. The company has a market cap of $23.64 billion, a PE ratio of -77.55 and a beta of 0.65.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter last year, the firm earned ($0.70) EPS. As a group, equities research analysts forecast that argenx will post -2.07 earnings per share for the current year.

Hedge Funds Weigh In On argenx

Several institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in argenx by 143.0% in the first quarter. JPMorgan Chase & Co. now owns 1,577 shares of the company’s stock valued at $497,000 after buying an additional 928 shares in the last quarter. Raymond James & Associates lifted its position in argenx by 19.4% in the 1st quarter. Raymond James & Associates now owns 4,534 shares of the company’s stock valued at $1,430,000 after acquiring an additional 738 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in argenx by 46.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,544 shares of the company’s stock valued at $1,117,000 after acquiring an additional 1,116 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in argenx by 4.4% in the 1st quarter. Bank of New York Mellon Corp now owns 6,447 shares of the company’s stock worth $2,033,000 after purchasing an additional 271 shares during the period. Finally, US Bancorp DE increased its holdings in argenx by 43.0% during the 1st quarter. US Bancorp DE now owns 1,798 shares of the company’s stock worth $566,000 after purchasing an additional 541 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.